Lodoco

The dosage of colchicine varies significantly depending on the condition being treated. It is imperative to follow the specific instructions provided by your healthcare provider.

Acute Gout Flare Treatment

For the treatment of an active gout flare, the standard FDA-approved regimen is:

• Initial Dose: 1.2 mg (two 0.6 mg tablets) at the first sign of a flare.
• Follow-up Dose: 0.6 mg (one tablet) one hour later.
• Maximum Dose: 1.8 mg total over a 1-hour period.
• Note: Taking more than this does not increase efficacy but significantly increases the risk of toxicity. Patients should wait at least 3 days before repeating this acute treatment course.

Gout Prophylaxis (Prevention)

To prevent flares, the typical dose is:

• Standard Dose: 0.6 mg once or twice daily.
• Maximum Dose: 1.2 mg per day.

Familial Mediterranean Fever (FMF)

• Standard Dose: 1.2 mg to 2.4 mg daily.
• Administration: This is usually given as a single dose or divided into two doses per day. Doses may be increased in increments of 0.3 mg/day based on response and tolerance.

Colchicine is FDA-approved for the treatment of FMF in children. It is NOT typically approved for gout in pediatric populations.

• Children 4-6 years: 0.3 mg to 1.8 mg per day.
• Children 6-12 years: 0.9 mg to 1.8 mg per day.
• Adolescents over 12 years: 1.2 mg to 2.4 mg per day.

Renal (Kidney) Impairment

Because colchicine is cleared by the kidneys, patients with renal disease are at a much higher risk of toxicity.

• Mild to Moderate (CrCl 30-80 mL/min): No adjustment is usually needed for prophylaxis, but caution is advised.
• Severe (CrCl < 30 mL/min): For gout prophylaxis, the starting dose may be 0.3 mg per day. For acute flare treatment, the dose is the same (1.2 mg + 0.6 mg), but the course should not be repeated more than once every 2 weeks.
• Dialysis: Colchicine is not removed by hemodialysis. A starting dose of 0.3 mg twice weekly may be used under strict supervision.

Hepatic (Liver) Impairment

In patients with mild to moderate liver impairment, dosage adjustments are generally not required. However, in patients with severe hepatic impairment, the dose must be reduced, and the patient must be monitored closely for signs of neuromuscular toxicity.

Elderly Patients

Patients over the age of 65 often have reduced kidney function. Healthcare providers typically start elderly patients at the lower end of the dosing range and monitor for gastrointestinal side effects, which are often the first sign of toxicity.

• With or Without Food: Colchicine can be taken with or without food. If it causes stomach upset, taking it with a meal may help.
• Administration: Tablets and capsules should be swallowed whole with a full glass of water. Do not crush or chew the tablets unless specifically instructed by a pharmacist.
• Consistency: For prophylaxis, take the medication at the same time every day to maintain steady levels in the bloodstream.
• Storage: Store at room temperature (68°F to 77°F) away from moisture, light, and heat.

If you miss a dose for prophylaxis, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not double the dose to make up for a missed one, as this can lead to toxicity.

A colchicine overdose is a medical emergency and can be fatal. There is no specific antidote. Signs of overdose often appear in stages:

1. 1Stage 1 (0-24 hours): Nausea, vomiting, abdominal pain, and severe diarrhea (which may be bloody).
2. 2Stage 2 (24-72 hours): Multi-organ failure, including kidney failure, heart rhythm abnormalities, and respiratory distress.
3. 3Stage 3 (>72 hours): Recovery (if the patient survives) often involves a rebound increase in white blood cells and temporary hair loss.

If an overdose is suspected, call 911 or your local poison control center immediately.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without medical guidance.

The most frequent side effects of colchicine involve the gastrointestinal (GI) tract. Because colchicine affects rapidly dividing cells, the lining of the stomach and intestines is particularly sensitive.

• Diarrhea: This is the most common side effect. It can range from mild loose stools to severe, watery diarrhea. In clinical trials, up to 23% of patients taking high doses for acute flares experienced diarrhea.
• Nausea and Vomiting: These symptoms often occur alongside diarrhea. They are usually dose-dependent, meaning they are more likely at higher doses.
• Abdominal Pain: Cramping or general discomfort in the stomach area is common.

For many patients, these GI symptoms are the first sign that the dose is too high or that toxicity is developing. If you experience severe diarrhea or vomiting, you should contact your doctor immediately.

• Fatigue and Malaise: Some patients report feeling generally unwell or tired while taking the medication.
• Headache: Mild to moderate headaches have been reported in a small percentage of patients.
• Biliary Obstruction: In rare cases, colchicine can affect bile flow, particularly in those with pre-existing liver issues.

• Alopecia (Hair Loss): This is usually reversible upon discontinuation of the drug.
• Azoospermia: Colchicine may interfere with sperm production (low sperm count), though this is typically reversible.
• Dermatological Reactions: Rashes, purpura (purple spots on the skin), and itching have been observed.

> Warning: Stop taking Colchicine and call your doctor immediately if you experience any of these serious symptoms. These may indicate systemic toxicity or a severe adverse reaction.

• Neuromuscular Toxicity (Myopathy): This involves muscle pain, weakness, or 'heaviness' in the limbs. In severe cases, it can lead to rhabdomyolysis, a condition where muscle tissue breaks down and releases a protein (myoglobin) into the blood that can damage the kidneys. This risk is higher in elderly patients and those taking statins.
• Blood Dyscrasias: Colchicine can suppress the bone marrow, where blood cells are made. This can lead to:
• Leukopenia/Neutropenia: Low white blood cell count, increasing the risk of serious infection.
• Thrombocytopenia: Low platelet count, leading to easy bruising or unusual bleeding.
• Aplastic Anemia: A condition where the body stops producing enough new blood cells.
• Hepatotoxicity: Signs of liver damage, such as yellowing of the eyes or skin (jaundice), dark urine, or upper right-sided stomach pain.
• Severe Hypersensitivity: Though rare, anaphylaxis can occur, characterized by swelling of the face/throat, difficulty breathing, and hives.

When taken for long periods (years), such as for FMF or chronic gout prophylaxis, patients must be monitored for:

• Vitamin B12 Malabsorption: Colchicine can interfere with the way the intestines absorb Vitamin B12, potentially leading to deficiency and anemia over time.
• Chronic Myopathy: Persistent muscle weakness that develops slowly. This is often misdiagnosed as aging or other conditions in elderly patients.
• Peripheral Neuropathy: Numbness, tingling, or 'pins and needles' sensations in the hands and feet due to nerve damage.

No FDA black box warnings currently exist for Colchicine. However, the FDA has issued multiple safety communications regarding the risk of fatal drug interactions and the dangers of using intravenous colchicine (which is no longer marketed in the U.S.). The most critical safety warning emphasizes that combining colchicine with strong CYP3A4 inhibitors (like clarithromycin) or P-gp inhibitors (like cyclosporine) in patients with renal or hepatic impairment has resulted in fatalities.

Report any unusual symptoms, especially muscle pain or severe diarrhea, to your healthcare provider immediately. Early detection of side effects is key to preventing serious toxicity.

Colchicine is a medication with a narrow therapeutic index. This means that the range between a dose that is effective and a dose that is toxic is very small. Because of this, patients must be extremely vigilant about following dosing instructions and recognizing early signs of toxicity. Colchicine toxicity can be cumulative, meaning it builds up in the body over time if not cleared properly by the kidneys or liver.

As of 2024, there are no FDA black box warnings for oral colchicine. However, the absence of a black box warning does not imply that the drug is without risk. The primary safety concern is the potential for life-threatening drug interactions and the risk of toxicity in patients with pre-existing organ dysfunction.

Neuromuscular Toxicity

Colchicine can cause significant damage to muscles and nerves (neuromyopathy). This risk is greatly increased in patients taking other medications that affect muscles, such as statins (cholesterol drugs like atorvastatin) or fibrates. Symptoms include muscle weakness, aching, and numbness. If you have unexplained muscle pain, contact your doctor immediately.

Blood Disorders (Myelosuppression)

Colchicine can interfere with the production of blood cells in the bone marrow. This can lead to dangerously low levels of white blood cells (which fight infection), red blood cells (which carry oxygen), and platelets (which help blood clot). Patients with pre-existing blood disorders should use colchicine with extreme caution.

Renal and Hepatic Impairment

Since colchicine is cleared by both the kidneys and the liver, any decrease in the function of these organs can cause the drug to accumulate to toxic levels. Your doctor should perform blood tests to check your kidney and liver function before you start this medication and periodically during treatment.

Allergic Reactions

While rare, some patients may develop a hypersensitivity to colchicine. Seek emergency care if you experience hives, swelling of the lips or tongue, or difficulty breathing.

If you are taking colchicine long-term, your healthcare provider will likely require regular monitoring, including:

• Complete Blood Count (CBC): To monitor for bone marrow suppression.
• Creatinine/BUN: To assess kidney function and adjust dosing if necessary.
• Liver Function Tests (LFTs): To ensure the liver is processing the drug safely.
• Creatine Kinase (CK): If you develop muscle pain, this test can check for muscle breakdown (rhabdomyolysis).

Colchicine generally does not cause drowsiness or impair cognitive function. However, if you experience side effects like fatigue, dizziness, or muscle weakness, you should avoid driving or operating heavy machinery until you know how the medication affects you.

Alcohol should be avoided or strictly limited while taking colchicine for gout. Alcohol increases the levels of uric acid in the blood, which can trigger the very gout flares you are trying to treat. Additionally, heavy alcohol use can stress the liver, potentially affecting how colchicine is metabolized.

For acute gout flares, you will stop taking the medication once the flare has subsided (usually after the two-dose regimen). For prophylaxis or FMF, do not stop taking the medication suddenly without consulting your doctor, as this can lead to a rapid return of symptoms or a severe inflammatory flare.

> Important: Discuss all your medical conditions, especially kidney or liver disease, with your healthcare provider before starting Colchicine.

There are several drugs that, when taken with colchicine, can cause the drug to reach fatal levels in the blood. These are primarily strong CYP3A4 inhibitors and P-glycoprotein (P-gp) inhibitors.

NEVER use colchicine with the following if you have renal or hepatic impairment:

• Clarithromycin and Erythromycin: These antibiotics significantly block the metabolism of colchicine.
• Ketoconazole and Itraconazole: Potent antifungal medications.
• Ritonavir and Atazanavir: HIV protease inhibitors.
• Cyclosporine: An immunosuppressant used in organ transplants.

The clinical consequence of these combinations is systemic colchicine toxicity, which can lead to multi-organ failure and death. Even in patients with normal organ function, these combinations require a massive reduction in colchicine dosage.

• Statins (e.g., Atorvastatin, Simvastatin): Both statins and colchicine can cause muscle damage (myopathy). Taking them together increases this risk synergistically. Patients should be monitored for muscle pain or weakness.
• Digoxin: This heart medication can increase the risk of colchicine toxicity, and colchicine may also affect digoxin levels.
• Fibrates (e.g., Fenofibrate): Like statins, these increase the risk of muscle breakdown.

• Diltiazem and Verapamil: These calcium channel blockers are moderate CYP3A4 inhibitors. They can increase colchicine levels, necessitating a lower colchicine dose (e.g., a maximum of 0.6 mg per day for prophylaxis).
• Amiodarone: Used for heart rhythm issues, it can increase colchicine exposure.

• Grapefruit and Grapefruit Juice: Grapefruit is a potent inhibitor of the CYP3A4 enzyme in the gut. Drinking grapefruit juice while taking colchicine can significantly increase the amount of drug that enters your bloodstream, potentially leading to toxicity. It is best to avoid grapefruit products entirely.
• High-Fiber Diets: While not a direct interaction, very high fiber intake might slightly alter the absorption of many medications, though this is rarely clinically significant for colchicine.

• St. John's Wort: This herbal supplement induces (speeds up) CYP3A4 enzymes. This could potentially lower the levels of colchicine in your blood, making it less effective at preventing flares.
• Curcumin/Turmeric: While generally safe, very high doses of curcumin can inhibit P-gp, which might theoretically increase colchicine levels.

Colchicine can cause false-positive results in urine tests for hemoglobin or albumin. It may also interfere with certain laboratory tests for urinary steroids. Always inform the laboratory staff that you are taking colchicine before undergoing tests.

Summary Table of Management

| Interacting Agent | Mechanism | Clinical Consequence | Management |

|---|---|---|---|

| Strong CYP3A4 Inhibitors | Enzyme Inhibition | Fatal Toxicity | Contraindicated in renal/hepatic impairment; reduce dose by 75% in others |

| Statins | Pharmacodynamic | Rhabdomyolysis | Monitor for muscle pain; consider temporary statin pause during acute flare treatment |

| P-gp Inhibitors | Efflux Inhibition | Increased Drug Levels | Avoid combination or reduce dose significantly |

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication review is the only way to prevent dangerous interactions.

Colchicine must NEVER be used in the following circumstances:

1. 1Renal or Hepatic Impairment + CYP3A4/P-gp Inhibitors: This is the most critical contraindication. If a patient has any degree of kidney or liver failure AND is taking a drug that blocks the enzymes that clear colchicine (like clarithromycin or cyclosporine), they must not take colchicine. The drug will build up rapidly, and because it cannot be cleared, it will cause life-threatening systemic toxicity.
2. 2Known Hypersensitivity: Patients who have had a severe allergic reaction to colchicine or any of the inactive ingredients in the tablet (such as lactose) should not take the medication.

These are conditions where the risk of taking colchicine may outweigh the benefits, or where extreme caution and lower doses are required:

• Severe Renal Impairment (CrCl < 30 mL/min): While not an absolute contraindication for all uses, it requires very careful dosing. For acute flares, the dose should not be repeated more than once every two weeks.
• Severe Hepatic Impairment: Patients with advanced cirrhosis or liver failure are at high risk for neuromuscular toxicity and should only use colchicine if no safer alternatives exist.
• Pre-existing Blood Dyscrasias: Patients with low white blood cell counts or anemia may see their condition worsen due to colchicine's effect on the bone marrow.
• Gastrointestinal Disease: Patients with severe inflammatory bowel disease or gastric ulcers may find that colchicine's GI side effects exacerbate their condition.

There are no commonly used drugs that share a direct cross-sensitivity with colchicine, as it is a unique alkaloid. However, patients who are sensitive to other Colchicum species or related plant alkaloids should be monitored closely for allergic reactions.

> Important: Your healthcare provider will evaluate your complete medical history, including kidney and liver function tests, before prescribing Colchicine. Do not share your medication with others, as their medical history may make the drug dangerous for them.

FDA Pregnancy Category C (under the old system). Data on the use of colchicine in pregnant women are somewhat limited but generally reassuring for certain conditions.

• FMF and Pregnancy: For women with Familial Mediterranean Fever, the consensus among specialists (and supported by the American College of Rheumatology) is that colchicine should usually be continued during pregnancy. Untreated FMF flares can lead to pregnancy complications and amyloidosis. Studies have not shown a clear increase in the risk of major birth defects when used for FMF.
• Gout and Pregnancy: Gout is rare in women of childbearing age. If it occurs, healthcare providers often prefer other treatments unless colchicine is deemed absolutely necessary.
• Risks: Colchicine crosses the placenta. High doses in animal studies have shown teratogenic effects (birth defects), but these doses were much higher than human therapeutic doses.

Colchicine is excreted into human breast milk. The American Academy of Pediatrics considers colchicine to be generally compatible with breastfeeding, as the amount the infant receives is typically low. However, because colchicine can affect cell division, nursing infants should be monitored for side effects like diarrhea or vomiting. Consult your pediatrician before breastfeeding while on this medication.

• Approved Use: Colchicine is FDA-approved for the treatment of FMF in children aged 4 years and older. Dosing is weight-based or age-based and must be carefully managed by a pediatric specialist.
• Safety: The safety profile in children for FMF is similar to that in adults. Long-term effects on growth and development have not been extensively studied, but no major concerns have been identified in children treated for FMF over many years.
• Non-Approved Use: Colchicine is not typically used for gout in children, as gout is an adult-onset condition related to long-term uric acid levels.

Patients over age 65 require special consideration:

• Renal Clearance: Natural decline in kidney function with age increases the risk of colchicine buildup.
• Fall Risk: Neuromuscular toxicity (muscle weakness) can increase the risk of falls in the elderly.
• Polypharmacy: Older adults are more likely to be taking interacting medications like statins or diltiazem.
• Dosing: Doctors often start at 0.3 mg per day or 0.6 mg every other day for prophylaxis in elderly patients.

In patients with a Glomerular Filtration Rate (GFR) below 30 mL/min, the clearance of colchicine is reduced by approximately 75%.

• Dose Adjustment: For gout prophylaxis, the dose should be reduced to 0.3 mg once daily or 0.6 mg every two to three days.
• Monitoring: These patients need frequent blood work to check for early signs of bone marrow suppression.

In patients with severe hepatic impairment, the clearance of colchicine is significantly reduced. While no specific GFR-like formula exists for liver dosing, doctors use the Child-Pugh classification. For patients with Child-Pugh Class C (severe), a dose reduction of 50% or more is typically recommended, and acute flare treatments should be avoided if possible.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have underlying organ disease.

Colchicine's molecular mechanism is centered on its binding to beta-tubulin. It forms a 'colchicine-tubulin complex' that prevents the addition of new tubulin molecules to the growing end of microtubules. This 'capping' of the microtubule ends leads to the disassembly of existing microtubule polymers.

In the context of inflammation:

1. 1Neutrophil Inhibition: By disrupting microtubules, colchicine prevents neutrophils from changing shape, which they must do to crawl toward the site of inflammation (chemotaxis).
2. 2Inflammasome Suppression: Recent research shows colchicine inhibits the NLRP3 inflammasome, a protein complex that triggers the release of Interleukin-1 beta (IL-1β), a major driver of gout pain.
3. 3Adhesion Molecules: It reduces the expression of 'velcro-like' molecules on the surface of blood vessels, making it harder for inflammatory cells to stick to and exit the bloodstream into the joint.

• Onset of Action: For an acute gout flare, pain relief typically begins within 12 to 24 hours of the first dose, with maximum effect at 48 to 72 hours.
• Duration: The anti-inflammatory effects can persist for several days after the last dose due to the slow release of the drug from white blood cells.
• Tolerance: There is no evidence that patients develop a tolerance to colchicine's anti-inflammatory effects over time.

| Parameter | Value |

|---|---|

| Bioavailability | ~45% |

| Protein Binding | ~39% (primarily Albumin) |

| Half-life | 27–31 hours (Healthy Adults) |

| Tmax | 0.5–3.0 hours |

| Metabolism | Hepatic (CYP3A4) |

| Excretion | Renal (40-65% unchanged), Biliary/Fecal |

| Volume of Distribution | 5–8 L/kg |

• Molecular Formula: $C_{22}H_{25}NO_6$
• Molecular Weight: 399.44 g/mol
• Solubility: Soluble in water (1 in 25), freely soluble in alcohol and chloroform.
• Description: A pale yellow powder that darkens on exposure to light. It is a tricyclic alkaloid consisting of three rings: a trimethoxyphenyl ring, a tropolone ring, and a seven-membered nitrogen-containing ring.

Colchicine is an Alkaloid [EPC] and an anti-gout agent. While it has anti-inflammatory properties, it is not a traditional NSAID. It is unique in its class, with no other medication sharing its exact mechanism of microtubule disruption for the treatment of gout.